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Summary
Mutations in microtubule-associated protein tau re-
cently have been identified in familial cases of fronto-
temporal dementia (FTD). We report the frequency of
tau mutations in a large population-based study of FTD
carried out in the Netherlands from January 1994 to
June 1998. Thirty-seven patients had1 first-degree rel-
ative with dementia. A mutation in the tau gene was
found in 17.8% of the group of patients with FTD and
in 43% of patients with FTD who also had a positive
family history of FTD. Three distinctmissensemutations
(G272V, P301L, R406W) accounted for 15.6% of the
mutations. These three missense mutations, and a single
amino acid deletion (DK280) that was detected in one
patient, strongly reduce the ability of tau to promote
microtubule assembly. We also found an intronic mu-
tation at position 33 after exon 9, which is likely to
affect the alternative splicing of tau. Tau mutations are
responsible for a large proportion of familial FTD cases;
however, there are also families with FTD in which no
mutations in tau have been found, which indicates locus
and/or allelic heterogeneity. The different taumutations
may result in disturbances in the interactions of the pro-
tein tau with microtubules, resulting in hyperphosphor-
ylation of tau protein, assembly into filaments, and sub-
sequent cell death.
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Introduction
Frontotemporal dementia (FTD) is a form of presenile
dementia characterized by behavioral changes, cognitive
decline, personality changes, speech deterioration, and,
later in the disease, decline of memory. Sometimes, par-
kinsonian symptoms are prominent (Brun 1987; Knop-
man et al. 1990). Atrophy of the frontal and/or temporal
cortex, as well as of the basal ganglia and substantia
nigra, are the characteristic neuropathological features.
Neuronal loss, gray-matter and white-matter gliosis, and
superficial cortical spongiform changes generally are
found in the cortex and some subcortical areas (Brun
1987; Lund and Manchester Groups 1994).
Prevalence of FTD in the Netherlands is estimated to
vary between 1.2/106 in the age group of 30–40 years
and 28.0/106 in the age group of 60–70 years (Stevens
et al. 1998). FTD can occur in a sporadic form, but
30%–50% of persons with FTD have been found to
have a positive family history of dementia (Gustafson
1987; Neary et al. 1988; Knopman et al. 1990; Stevens
et al. 1998).
A number of families with an autosomal dominant
mode of inheritance and almost complete penetrance
have been described, and 13 have been linked genet-
ically to chromosome 17q21-22; these are now referred
to as “frontotemporal dementia and parkinsonism
linked to chromosome 17” (FTDP-17 [MIM 601630];
Wilhelmsen et al. 1994; Petersen et al. 1995; Wijker et
al. 1996; Yamaoka et al. 1996; Baker et al. 1997; Poor-
kaj et al. 1998; Foster et al. 1997; Froelich et al. 1997;
Heutink et al. 1997; Murrell et al. 1997; Lendon et al.
1998).
Most, if not all, families with FTDP-17 show micro-
tubule-associated protein tau deposits in neurons or in
both neurons and glial cells. In some FTDP-17 families,
the tau deposits are identical to those found in Alzheimer
disease (AD; Spillantini et al. 1996): they are present in
neurons and consist of paired helical and straight fila-
ments, which contain all six brain tau isoforms. Other
families show tau deposits, in neurons and in glial cells,
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Table 1
PCR Primers for Genomic Amplification of Tau Exons (5′r3′)
Exon Forward Reverse
Exon Size
(bp)
PCR Product
(bp)
1 CAACACTCCTCAGAACTTATC CAGTGATCTGGGCCTGCTGTG 150 228
2 CACAGGGAGCGATTTTCAGC CCACGCTGTCCTGCAAAGC 87 339
3 GGGCTGCTTTCTGGCATATG CCTCACTTCTGTCACAGGTC 87 297
4 GGATGTGAACTTTCCTGAATG GAGCTCAGGTCCAAATGATC 66 271
5 CAGTGAAAATGGAGTGTGAC CAGCTGCAGAGCTCCGTGGC 56 136
7 CTAGGAGGCCAAGGGTCAC GAGAGCTTCAGCTTCCTCTAAG 127 300
9 CGAGTCCTGGCTTCACTCC CTTCCAGGCACAGCCATACC 266 379
10 GGTGGCGTGTCACTCATCC GGTGGCGTGTCACTCATCC 93 200
11 CTTCTCATTGAGTTACACCC CTCACCAGGACTCCTCCAC 82 174
12 AGATGCTCTTGTGTGTGTTGTG CAGCATCCAACCCACCCTAC 113 173
13 CTTTCTCTGGCACTTCATCTC CCTCTCCACAATTATTGACCG 208 299
which consist of wide, twisted ribbons and contain only
tau isoforms with four microtubule-binding repeats
(Spillantini et al. 1997).
The microtubule-associated protein tau is believed to
function in the assembly and stabilization of microtu-
bules. The tau protein isoforms found in human brain
samples are encoded by 11 exons (Andreadis et al.
1992). A total of six different major tau mRNA tran-
scripts are generated, resulting from alternative splicing,
which encode proteins of 352–44l amino acids (Goedert
et al. 1989a). The alternative splicing of exon 10 gen-
erates tau proteins with three or four microtubule-bind-
ing motifs that are imperfect repeats of 31 or 32 residues
each (Goedert et al. 1989b).
Recently, we and others sequenced the tau gene in
FTDP-17 families (Hutton et al. 1998; Poorkaj et al.
1998; Spillantini et al. 1998b) and identified missense
mutations in coding exons 9, 10, 12, and 13, which are
predicted to affect the microtubule-binding properties of
the tau protein (MIM 157140). Mutations also were
found in a predicted stem-loop structure at the 5′ side
of the intron, between exons 10 and 11, causing a shift
in the normal splicing ratio of transcripts containing
exon 10, and resulting in a higher proportion of four-
repeat tau isoforms. In the present study, we report the
contribution of tau mutations as a cause of FTD in a
large group of patients ascertained in a genetic epide-
miological study of FTD in the Netherlands.
Patients and Methods
Patients
Ninety patients with FTD were identified in a genetic-
epidemiological study in the Netherlands (population
∼15million), between January 1994 and June 1998. Part
of this study has been described elsewhere (Stevens et
al. 1998). Neurologists, psychiatrists, and physicians at
nursing homes were asked to report all patients with
FTD with age at onset !65 years, irrespective of family
history. We excluded secondary cases of FTD mentioned
in family history, to avoid referral bias resulting from
familial clustering. The diagnostic criteria were the clin-
ical and neuroimaging findings defined by the Man-
chester and Lund groups (1994). Progressive behavioral
changes and speech disturbances were characteristic
early symptoms in all patients, whereas memory prob-
lems were initially absent. The diagnosis of FTD was
supported by neuropsychological test results at ascer-
tainment or by review of previous neuropsychological
reports, when available. All patients showed frontotem-
poral atrophy, on computed tomography or magnetic
resonance scan, or showed anterior hypoperfusion on
single-photon-emission–computed tomography. Two in-
dependent neurologists, blinded for family history and
neuroimaging, checked the clinical diagnosis, and a neu-
roradiologist with no knowledge of the patients’ family
history of FTD evaluated the presence of neuroimaging
changes. Data on dementia and other neurodegenerative
disorders in first-degree relatives were collected by use
of a family questionnaire.
The study was approved by the Medical Ethics Com-
mittee of The University Hospital Dijkzigt. Informed
consent for venipuncture for DNA studies was obtained
from the spouse or from a first-degree relative of each
patient.
DNA studies
Blood samples were collected from 90 patients with
FTD. DNA was prepared according to standard pro-
cedures (Miller et al. 1988). Exons of the tau gene were
amplified by use of specific primers derived from the 5′
and 3′ intronic sequences (table 1). The annealing tem-
perature for all primer pairs was 58C. Amplification
conditions were as follows: reaction volume was 50 ml,
with a final concentration of 10 mM Tris-HCl (pH 8.3),
50 mM KCl, 1.5 mM MgCl2, and 200 mM dNTPs; Taq
polymerase at 1.5 units/50 ml; primers at 25 pmol/ml;
and 50 ng template genomic DNA. The PCR reactions
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were analyzed on a 2% agarose gel to verify the size and
quantity of the PCR product.
For SSCP, 3 ml PCR product was applied to the Phar-
macia GenePhor Electrophoresis system. Gels were run
for 70 min at 18C and for 90 min at 5C. Running
conditions for both gels were 600V, 400 mA, and 30W,
respectively. Bands then were visualized by use of a DNA
silver staining kit (Pharmacia) in a Hoefer automated
gel stainer. All 11 coding exons of the tau gene, including
flanking intronic sequences, were amplified from ge-
nomic DNA of each FTD patient by use of PCR primers
specified in table 1. SSCP analysis was performed on
exons 1, 2, 3, 4, 5, 7, 9, 11, and 13, and the exons
presenting band shifts were subsequently analyzed by
direct sequence analysis of the PCR products, on an
automated DNA sequencer (ABI 377), by use of the
BigDye terminator cycle sequencing kit. Exons 10 and
12 of all 90 cases of FTD were sequenced directly on
both strands.
Oligonucleotides with a length of 15 bases for allele-
specific oligo (ASO) hybridization were designed for the
mutated and normal sequence. ASO hybridizations were
performed at 42C for 1 h. Filters were washed, until a
final stringency of 0.3XSSC/0.1SDS was obtained, for
15 min at 42C.
Microtubule Assembly Assays
Site-directed mutagenesis was used in the four-repeat
412–amino acid isoform of tau (expressed from cDNA
clone htau46; Goedert et al. 1989a), to change the pro-
line residue at position 301 to a leucine (P301L) and to
delete the lysine at position 280 (DK280), in the num-
bering of the 441–amino acid isoform of human tau.
Wild-type and mutated tau proteins were expressed in
Escherichia coli BL21 (DE3), as described elsewhere
(Goedert and Jakes 1990). Bacterial pellets were resus-
pended in 50 mM PIPES, 1 mM EGTA, 1 mM DTT,
0.5 mM PMSF, and 0.5 mg/ml leupeptin (pH 6.8), fol-
lowed by a min sonication on ice, by use of a2# 1
Kontes Micro Ultrasonic Cell Disrupter. The homogen-
ates were centrifuged at for 15 min, and27,000 # g
the supernatants were filtered through a 0.45 mm Acro-
disc. The filtrate was loaded onto a phosphocellulose
column (bed volume 2 ml) that was equilibrated in ex-
traction buffer. The column was washed in extraction
buffer and then in extraction buffer  0.1 M NaCl.
Protein was eluted batchwise with 6 ml extraction buffer
containing 0.3 M NaCl. This was followed by overnight
dialysis against a saturated ammonium sulphate solution
and then precipitation by a 10-min centrifugation at
50,000 rpm (Beckman TL100). The pellet was resus-
pended in extraction buffer and reprecipitated by ad-
dition of an equal volume of saturated ammonium sul-
phate solution. After centrifugation, the pellet was
resuspended in 1 ml extraction buffer containing 0.5 M
NaCl and 1% 2-mercaptoethanol and was then boiled
for 3 min. After a 10-min centrifugation at 50,000 rpm,
the supernatant was loaded onto a NAP10 column equil-
ibrated in 80 mM PIPES, 1 mM EGTA, 0.2 mMMgCl2,
1 mM DTT (microtubule assembly buffer minus GTP),
and eluted with 1.5 ml of the same buffer. GTP was
added until a final concentration of 1 mM. Tau protein
concentrations were determined by densitometry (Mo-
lecular Dynamics), with bovine serum albumin used as
the standard. In all experiments, wild-type and mutant
proteins were expressed and purified in parallel.
Purified recombinant wild-type and mutated htau46
(0.1 mg/ml, 2.3 mM) proteins were incubated with bo-
vine brain tubulin (1 mg/ml, 20 mM, Cytoskeleton, Inc.)
in assembly buffer at 37C, as described elsewhere (Has-
egawa et al. 1997). The assembly of tubulin into mi-
crotubules was monitored over time by a change in tur-
bidity at 350 nm.
Results
The group of patients with FTD consisted of 59
women and 31 men. The mean age at onset of FTD was
54.6 years 8.4 years, with a mean duration of illness
of 5.4 years  2.7 years. Family history of dementia
was positive in 37 patients (41.1%). The clinical diag-
nosis of FTD was confirmed by pathological examina-
tion in 13 cases. Pick disease was diagnosed in three
cases. Nine patients died without pathological verifi-
cation.
We systematically performed SSCP and sequence anal-
ysis in our collection of patients with FTD, to detect
mutations in the tau gene. Thirteen sites were detected
in patients who were heterozygous for the sequence al-
terations; no homozygous sequence alterations were de-
tected. To determine whether these alterations were po-
tential disease-related mutations or nonpathogenic
polymorphisms, we looked for the presence of each se-
quence alteration in healthy family members or in 192
(96 males and 96 females) unaffected individuals from
the Dutch population, using ASO hybridization.
Eight of the 13 sequence alterations also were found
in healthy control individuals and were identified as
non–disease-related polymorphisms (table 2). These
eight base changes are all silent mutations that do not
affect the amino acid sequence of tau protein. Five se-
quence alterations were not detected in healthy family
members or in the 192 control individuals and therefore
could be disease-related mutations (table 3).
Three different missense mutations were detected in
a total of 14 patients, resulting in the following amino
acid substitutions: G272V, P301L, and R406W, num-
bered according to the longest isoform of human brain
tau (Goedert et al. 1989a; table 3). In addition, we found
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Table 2
Polymorphic Sites Identified in the Tau Gene
Position in Tau Gene
Nucleotide
Change
Frequency in
FTD Cases (%)
Exon 1 position 13 from ATG ArG 18
3′ Exon 2  18 CrT 18
3′ Exon 3  9 ArG 33
Exon 7 codon 176 GrA 18
Exon 9 codon 227 ArG 30
Exon 9 codon 255 TrC 30
Exon 9 codon 270 GrA 6
3′ Exon 11  34 GrA 28
NOTE.—Sequence alterations were also detected in healthy family
members of patients or in a series of Dutch healthy controls.
Figure 1 Effects of the DK280 mutation in tau on the ability of
four-repeat htau46 (412–amino acid isoform of human tau) to promote
microtubule assembly. Comparison with the P301L missense mutation
in tau. Polymerization of tubulin induced by wild-type htau46, htau46
DK280, and htau46 P301L, as monitored over time by turbidimetry.
A typical experiment is shown; similar results were obtained in three
separate experiments.
a single amino acid deletion (DK280) in one patient and
a base change (GrA) at position 33 in the intron after
exon 9 in another patient.
In 17.8% of all patients with FTD, a mutation was
detected (table 3). All patients with a mutation had a
positive family history of dementia, except the patient
with the DK280 mutation, who had a positive family
history of Parkinson disease.
In genetic diseases, pathogenic mutations must be ab-
sent in healthy control individuals and must segregate
with the disease phenotype. The G272V mutation, re-
sulting from the nucleotide change 1051GrT in exon
9, was found in two patients (2.2%). Both patients were
members of the HFTD II family, for which segregation
of the mutation with the disease has been reported (Hut-
ton et al. 1998).
The P301L mutation, resulting from the nucleotide
change CrT in exon 10, was present in 11 cases
(12.2%). Cosegregation of the P301L mutation for five
affected family members has been described elsewhere,
for the HFTD I family (Hutton et al. 1998). Six addi-
tional cases were found in the present study. Nine of the
11 total cases with a P301L mutation share a common
ancestor, on the basis of a genealogical study and con-
struction of haplotypes for polymorphic markers in and
around the tau gene.
The R406W mutation, resulting from the nucleotide
change CrT in exon 13, initially was observed in a single
patient (1.1%). From the relatively small R406W family
(HFTD IV), three affected individuals were tested, and
the mutation segregated with the disease phenotype.
The DK280 mutation, resulting from a deletion of the
nucleotides AAG in exon 10, was detected in a single
case (1.1% ). The base change GrA at position 33 in
the intron after exon 9 was also observed, in one patient
(1.1%) from a small family with no additional affected
family members available for study. Thus, additional ev-
idence that this mutation is pathogenic and not merely
a rare polymorphism can be obtained only by in vitro
studies.
The present study includes 30 independent families,
each with at least two affected family members, that
could not be linked to a common ancestor by genea-
logical studies or haplotype data. In seven (23.3%) of
these families, a mutation in the tau gene was detected.
Tau protein promotes microtubule assembly, stabilizes
microtubules, and affects their dynamic behavior. The
G272V, P301L, and R406W mutations strongly reduce
the ability of tau protein to promote microtubule assem-
bly (Hasagawa et al. 1999). To strengthen the evidence
that the DK280 reported here is indeed pathogenic, we
performed microtubule assembly assays using recom-
binant wild-type four-repeat tau and tau with theD280K
mutation. We compared their ability to promote micro-
tubule assembly with that of the same four-repeat tau
isoform with the P301L mutation. The effect of the
D280K mutation on microtubule assembly was dramatic
and larger than the effect of the P301L mutation (fig.
1). Recombinant tau protein with the D280K mutation
showed a greatly reduced ability (!1% of activity of
wild-type tau, after 2 min) to promote microtubule as-
sembly (fig. 1). The effect was much larger than for the
other known missense mutations in tau.
Discussion
We describe here the results of a systematic screen for
mutations in the microtubule-associated protein tau in
90 patients with FTD, obtained through a genetic epi-
demiological study performed in the Netherlands since
January 1994. Our analysis revealed a mutation in the
tau gene in 17.8% of patients with FTD and in 40.5%
of patients with a positive family history for dementia.
Although we excluded secondary cases to avoid referral
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Table 3
Mutations Identified in the Tau Gene
Exon
Nucleotide
Change
Amino Acid
Change
No. of
Cases
No. with Positive
Family History
9 GrT G272V 2 2
3′ exon 9 33 GrA ) 1 1
10 CrT P301L 11 11
10 DAAG DK280 1 0
NOTE—Positions are numbered according to the longest human
brain tau isoform (441 amino acids).
bias resulting from familial clustering, the 37 nuclear
families have been reduced to 30 independent families
by use of extensive genealogical studies and haplotype
analysis. In seven (23.3%) of these families, a mutation
in tau was detected.
Three distinct missense mutations, one 3-bp deletion,
and one mutation in the intron after exon 9 were found.
No nonsense mutations were found and none of the
previously described intronic mutations in the predicted
stem loop after exon 10 were found (Hutton et al. 1998;
Spillantini et al. 1998b). No large insertions or deletions
were detected.
In samples of adult human brain, six tau isoforms
were expressed from a total of 11 exons (Goedert et al.
1989a; Andreadis et al. 1992). In this study, we analyzed
all 11 coding exons. We used SSCP analysis for mutation
detection and, although we used different experimental
conditions, this method might detect effectively only
80%–90% of mutations present. Furthermore, addi-
tional sequences, such as coding exons that are expressed
in the peripheral nervous system, or regulatory elements,
such as the promoter region of tau, were not tested in
this study. That we did not find mutations in ∼60% of
the familial cases, and that we did not find a mutation
in patients from family HFTD III, which is linked to
chromosome 17 (Heutink et al. 1997), clearly indicate
that the present findings may constitute an underesti-
mate of the percentage of mutations in the tau gene in
cases of FTD.
We therefore currently are extending our mutational
analysis to the noncoding region of the tau gene. For
many familial cases, we could not determine whether
they were linked to chromosome 17, because additional
family members were not available. We therefore cannot
exclude locus heterogeneity for FTD.
Additional evidence that the G272V, P301L, and
R406W mutations are pathogenic comes from the ob-
servation that all three mutations segregated with the
clinical phenotype in families HFTD II, HFTD I (Hutton
et al. 1998), and HFTD IV, respectively. Furthermore,
the P301 substitution occurs in a highly conserved region
of the tau protein sequence. A proline residue is present
at the equivalent position in all species from which tau
has been sequenced. The G272V mutation in exon 9
also affects a highly conserved residue within the mi-
crotubule-binding domain. Within the imperfect repeat
sequences that make up the four microtubule-binding
domains, the G272V and P301L mutations affect po-
sitions that are separated by only one residue. Thus, for
P301L, the invariant PGGG motif in the binding repeat
becomes LGGG, and for G272V, it becomes PGVG. In
contrast to the P301L mutation (exon 10), the G272V
mutation (exon 9) affects all tau isoforms. Analysis of
tau filaments extracted from HFTD 1 brain samples has
revealed that the filaments are narrow, twisted ribbons
that consist mainly of four-repeat tau isoforms, which
is consistent with the P301L mutation only affecting
four-repeat tau isoforms (Spillantini 1998a). The
R406W missense mutation in exon 13 alters a highly
conserved residue near the C-terminus, outside the mi-
crotubule-binding repeats, in close proximity to residues
S396 and S404, that are phosphorylated in hyperphos-
phorylated filaments (Goedert 1993).
Experimental confirmation that the mutations are
pathogenic has been obtained by means of functional
studies of microtubule assembly. All three missense mu-
tations reduce the ability of tau to promote microtubule
assembly in vitro, with the P301L mutation having the
strongest effect (Hasegawa et al. 1999). In the present
study, we compared the effects of the P301L mutation
and of the DK280 deletion mutation on microtubule
assembly. Tau protein with the DK280 mutation showed
a strongly reduced ability to promote microtubule as-
sembly. This effect was much larger than for the P301L
mutation. The DK280 mutation is located in the exon
10 “linker region,” between two microtubule-binding
repeats that contain the following amino acids, starting
at amino acid 274, using the numbering for the longest
tau isoform: KVQIINKKLD. The deletion removes ei-
ther the second or the last lysine residue at position 280
or 281. Two other studies have used site-directed mu-
tagenesis to mutate the K280 and/or K281 residues
(Goode and Feinstein 1994; Trinczek et al. 1995). By
use of microtubule binding and assembly assays, it was
shown that the mutated proteins had a 3.6 times lower
affinity for microtubules than the wild-type tau. In ad-
dition, the dynamic instability of microtubules was in-
creased strongly, demonstrating that these lysine residues
are critical for tau function.
The patient with the DK280 mutation has a negative
family history of dementia, but his father was diagnosed
with Parkinson disease. Clark et al. (1998) recently have
reported a mutation that introduces an additional lysine
residue (N279K), directly adjacent to K280, in a family
with pallido-ponto-nigral degeneration. Characteristic
of the clinical phenotype in this family is the rapidly
progressive parkinsonism. Unfortunately, the limited
clinical and genetic data available for the patient with
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the DK280 mutation and other family members do not
permit us to determine the significance of these
similarities.
We could not determine whether the intronicmutation
after exon 9 at position 33 segregates with the clinical
phenotype, since no other family members were avail-
able. The mutation may affect the alternative splicing
pattern of tau, although the mechanism is not yet clear.
Exon 9 itself is not spliced alternatively, and no potential
stem-loop structure was observed after exon 9. No sam-
ple of brain material was available from the patient,
which precluded experiments to determine whether the
mutation causes a change in tau mRNA transcripts.
A possible explanation for the effect of the mutation
could come from two recent reports implicatingmultiple
copies of short intronic (A/U)GGG repeats in splicing
efficiency (Sirand-Pugnet et al. 1995; Cogan et al. 1997).
The disruption of these short motifs reduces splicing ef-
ficiency. In the 200 bp of intronic sequence currently
available, eight (A/U)GGG motifs were found. The33
GrA base change disrupts the first of these motifs. The
expected effect would be inhibition of splicing. We are
currently in the process of obtaining additional intronic
sequences, and we hope this will enable us to design an
assay for testing the significance of this mutation in vitro.
How can the mutations that have been found so far
provide an explanation of the clinical phenotype and
neurodegeneration found in patients? At first sight, the
missense and deletion mutations, on one hand, and the
intronic mutations, on the other hand, appear to pro-
duce opposite effects on tau function, whereas the clin-
ical phenotype of patients with these different types of
mutations is highly similar (Foster et al. 1997). Both the
missense and deletion mutations reduce the ability of
tau to promote microtubule assembly, which is the prod-
uct of microtubule nucleation and/or growth. The in-
tronic mutations lead to increased levels of four-repeat
tau isoforms (Hutton et al. 1998; Spillantini et al.
1998b), which could lead to an increase in microtubule
assembly. It is well established that four-repeat tau iso-
forms are better at promoting microtubule assembly
than are isoforms with three repeats (Goedert and Jakes
1990).
There is some evidence to suggest that tau may nu-
cleate microtubules in nerve cells (Bre´ and Karsenti
1990; Hirokawa 1994). A possible explanation of why
mutations with opposite effects do not seem to influence
clinical phenotype might be that a reduced ability to
promote microtubule assembly, resulting from the mis-
sense and deletion mutations, could lead to an excess in
free, unbound cytoplasmic tau. An increase in four-re-
peat tau isoforms, resulting from the intronic mutations,
similarly leads to an excess of four-repeat tau over avail-
able binding sites on microtubules, because three- and
four-repeat tau isoforms may bind to different sites on
microtubules, as has been suggested by Goode and Fein-
stein (1994). A reduced ability of tau molecules to in-
teract with microtubules thus could be the primary de-
fect resulting from the different mutations in tau. This
may in turn lead to the hyperphosphorylation of tau,
which could reinforce the primary effect of the muta-
tions. It is well known that hyperphosphorylated tau
from samples of brains affected by Alzheimer disease is
unable to bind microtubules or to promote microtubule
assembly (Bramblett et al. 1993; Yoshida and Ihara
1993). Over time, perhaps in conjunction with other
factors (Goedert et al. 1996), hyperphosphorylated tau
will then assemble into filaments. In addition to effects
on microtubule assembly and microtubule binding, mu-
tations in tau may also have additional, direct effects on
phosphorylation of tau and may favor its assembly into
filaments.
In this view, the formation of tau filaments is the gain
of the toxic function that is believed to underlie auto-
somal dominantly inherited, late-onset neurodegenera-
tive diseases (Goedert et al. 1998). Future studies will
show whether this view is correct or whether tau fila-
ment formation is only a by-product of the underlying
pathogenic process. It will be important to understand
how mutations in tau lead to neurodegeneration, be-
cause it is already clear that the tau gene is a major locus
of inherited dementing disease. The discovery of mu-
tations in the tau gene will advance the study of dementia
in general, since Alzheimer disease, the most common
dementing illness, is characterized by an abundant tau
pathology whose presence correlates with the degree of
cognitive impairment.
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